HCM — HUTCHMED (China) Ltd

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1648257 · Hong Kong
Last close
$14.40
Market Cap
$2.50B
52W High
$16.33
52W Low
$9.77
ADV30
47,574
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Dec 2025 — — — — 1,753,097,000 71,330,000 501,835,000
Jun 2025 — — — — 1,775,940,000 — 534,017,000

Balance + Analyst (yfinance extras)

Retained Earnings
$-378,643,000
Inventory
$41,129,000
Receivables
—
ST Investments
$1,295,945,000
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
12

Yahoo Snapshot (yfinance, live)

Total Revenue
$549,121,984
EBITDA
$-20,515,000
Free Cash Flow
$-18,880,250
Enterprise Value
$960,541,632
Total Cash
$1,376,455,936
Total Debt
$94,508,000
Shares Out
173,814,168
Trailing EPS
$0.10
Book Value
$7.25
ROE
1.5%
ROA
-1.2%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 548,512,000 -35,700,000 456,909,000 1,753,097,000 501,835,000 1,237,926,000 -64,657,000
Dec 2024 630,201,000 -40,610,000 37,729,000 1,274,196,000 502,343,000 759,929,000 497,000
Dec 2023 837,999,000 21,509,000 100,780,000 1,279,773,000 536,386,000 730,541,000 219,258,000
Dec 2022 426,409,000 -406,259,000 -360,835,000 1,029,445,000 392,575,000 610,367,000 -268,599,000

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$0.26

Max Pain — expiry 2027-02-19 (volume-derived — Yahoo OI feed degraded)

max pain strike: $15.00 · spot: $13.99 · call volume: 10 · put volume: 10
Expected Move to 2027-02-19: ±$5.38 (38.42%) — implied range $8.61 – $19.36 · ATM straddle on $15.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
XNCR Xencor Inc $2.59B $34.50 —
MBX MBX Biosciences, Inc. $2.64B $53.10 —
IDYA IDEAYA Biosciences, Inc. $2.65B $27.40 —
RCUS Arcus Biosciences, Inc. $2.36B $16.39 —
NAMS NewAmsterdam Pharma Co N.V. $2.33B $19.39 —

News headlines (Yahoo Finance, 1h cache)

HUTCHMED Highlights HMPL-A830 Pre-Clinical Data Presented at the 38th EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics
2026-11-19 00:00 · Yahoo
HUTCHMED Announces Expanded Coverage on National Reimbursement Drug List for ELUNATE® and ORPATHYS®
2026-11-16 04:00 · Yahoo
HUTCHMED (China) (AIM:HCM) Extends Lung Cancer Filing Run As Undervalued View Holds
2026-11-06 01:21 · Yahoo
HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Autoimmune Hemolytic Anemia
2026-11-05 00:00 · Yahoo
HUTCHMED Announces Regulatory Filings Accepted for Review for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer in Europe and Japan
2026-11-02 00:00 · Yahoo
HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Primary Immune Thrombocytopenia
2026-10-29 00:00 · Yahoo
Save the Date: HUTCHMED to Host Expert Insights Event on Recent Savolitinib Clinical Data in Non-Small Cell Lung Cancer
2026-10-27 00:00 · Yahoo
HUTCHMED Highlights SANOVO Phase III Data for ORPATHYS® plus TAGRISSO® in First-Line EGFR-Mutated Lung Cancer Presented at ESMO Congress 2026
2026-10-26 08:30 · Yahoo
HUTCHMED Highlights SAFFRON Global Phase III Data Presented at ESMO Congress 2026 and Simultaneously Published in The New England Journal of Medicine
2026-10-26 00:00 · Yahoo
UPDATE – International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 12, 2026
2026-11-09 16:56 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.